deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT01008462

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients With High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Sponsor: Fred Hutchinson Cancer Center

Conditions B-Cell Prolymphocytic Leukemia Hypodiploidy Loss of Chromosome 17p Plasma Cell Leukemia Progression of Multiple Myeloma or Plasma Cell Leukemia Recurrent Adult Hodgkin Lymphoma Recurrent Adult Non-Hodgkin Lymphoma Recurrent Childhood Hodgkin Lymphoma Recurrent Childhood Non-Hodgkin Lymphoma Recurrent Chronic Lymphocytic Leukemia Recurrent Plasma Cell Myeloma Recurrent Small Lymphocytic Lymphoma Refractory Childhood Hodgkin Lymphoma Refractory Chronic Lymphocytic Leukemia Refractory Non-Hodgkin Lymphoma Refractory Plasma Cell Myeloma Refractory Small Lymphocytic Lymphoma T-Cell Prolymphocytic Leukemia Waldenstrom Macroglobulinemia t(14;16) t(4;14)
Interventions Allogeneic Bone Marrow Transplantation Allogeneic Hematopoietic Stem Cell Transplantation Autologous Hematopoietic Stem Cell Transplantation Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation Carmustine Cyclophosphamide Cytarabine Etoposide Fludarabine Phosphate Laboratory Biomarker Analysis Melphalan Mycophenolate Mofetil Peripheral Blood Stem Cell Transplantation Tacrolimus Total-Body Irradiation
Updated 13 times since 2017 Last updated: May 31, 2019 Started: Mar 18, 2010 Primary completion: Jun 30, 2018 Completion: Jun 30, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates B-Cell Prolymphocytic Leukemia and Hypodiploidy and is currently completed. Fred Hutchinson Cancer Center leads this study, which shows 13 recorded versions since 2010 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Dec 2017 · 10 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Jan 2019 · 7 months · monthly snapshot~Jan 2019 – ~Jun 2019 · 5 months · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Jan 2021 · 18 months · monthly snapshot~Jan 2021 – ~May 2022 · 16 months · monthly snapshot~May 2022 – ~Dec 2022 · 7 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

  5. May 2022 — Dec 2022 [monthly]

    Completed PHASE2

▶ Show 8 earlier versions

  1. Jan 2021 — May 2022 [monthly]

    Completed PHASE2

  2. Jul 2019 — Jan 2021 [monthly]

    Completed PHASE2

  3. Jun 2019 — Jul 2019 [monthly]

    Completed PHASE2

  4. Jan 2019 — Jun 2019 [monthly]

    Completed PHASE2

    Status: Recruiting → Completed

  5. Jun 2018 — Jan 2019 [monthly]

    Recruiting PHASE2

  6. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  7. Feb 2017 — Dec 2017 [monthly]

    Recruiting PHASE2

  8. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fred Hutchinson Cancer Center
  • National Cancer Institute (NCI)
Data source: Fred Hutchinson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations